NovoEight

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

turoktocog alfa

Available from:

Novo Nordisk A/S

ATC code:

B02BD02

INN (International Name):

turoctocog alfa

Therapeutic group:

čimbenik zgrušavanja krvi VIII

Therapeutic area:

Hemofilija A

Therapeutic indications:

Liječenje i profilaksu krvarenja u bolesnika s hemofilijom A (nedostatak kongenitalnog faktora VIII). Novoeight se može koristiti za sve dobne skupine.

Product summary:

Revision: 13

Authorization status:

odobren

Authorization date:

2013-11-13

Patient Information leaflet

                                41
B. UPUTA O LIJEKU
42
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
NOVOEIGHT 250 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
NOVOEIGHT 500 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
NOVOEIGHT 1000 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
NOVOEIGHT 1500 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
NOVOEIGHT 2000 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
NOVOEIGHT 3000 IU PRAŠAK I OTAPALO ZA OTOPINU ZA INJEKCIJU
turoktokog alfa (humani koagulacijski faktor VIII (rDNK))
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
–
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
–
Ako imate dodatnih pitanja, obratite se liječniku.
–
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
–
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika. To uključuje i svaku
moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte dio 4.
ŠTO SE NALAZI U OVOJ UPUTI
1.
Što je NovoEight i za što se koristi
2.
Što morate znati prije nego počnete primjenjivati NovoEight
3.
Kako primjenjivati NovoEight
4.
Moguće nuspojave
5.
Kako čuvati NovoEight
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE NOVOEIGHT I ZA ŠTO SE KORISTI
NovoEight sadrži djelatnu tvar turoktokog alfa, humani koagulacijski
faktor VIII. Faktor VIII je
protein koji se prirodno nalazi u krvi i pomaže pri zgrušavanju.
NovoEight se koristi za liječenje i sprječavanje epizoda krvarenja u
bolesnika s hemofilijom A
(prirođeni nedostatak faktora VIII) i može se primjenjivati u svim
dobnim skupinama.
U bolesnika s hemofilijom A faktor VIII nedostaje ili nema ispravnu
funkciju. NovoEight zamjenjuje
taj „faktor VIII“ koji nedostaje ili ne djeluje pravilno te
pomaže u stvaranju krvnih ugrušaka na mjestu
krvarenja.
2.
ŠTO MORATE ZNATI PRIJE NEGO POČNETE PRIMJENJIVATI NOVOEIGHT
NEMOJTE PRIMJENJIVATI NOVOEIGHT:
•
ako ste alergični
na djelatnu tvar ili neki dru
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
NovoEight 250 IU prašak i otapalo za otopinu za injekciju
NovoEight 500 IU prašak i otapalo za otopinu za injekciju
NovoEight 1000 IU prašak i otapalo za otopinu za injekciju
NovoEight 1500 IU prašak i otapalo za otopinu za injekciju
NovoEight 2000 IU prašak i otapalo za otopinu za injekciju
NovoEight 3000 IU prašak i otapalo za otopinu za injekciju
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
NovoEight 250 IU prašak i otapalo za otopinu za injekciju
Jedna bočica s praškom nominalno sadrži 250 IU humanog
koagulacijskog faktora VIII (rDNK),
turoktokoga alfa.
Nakon rekonstitucije, NovoEight sadrži približno 62,5 IU/ml humanog
koagulacijskog faktora VIII
(rDNK), turoktokoga alfa.
NovoEight 500 IU prašak i otapalo za otopinu za injekciju
Jedna bočica s praškom nominalno sadrži 500 IU humanog
koagulacijskog faktora VIII (rDNK),
turoktokoga alfa.
Nakon rekonstitucije, NovoEight sadrži približno 125 IU/ml humanog
koagulacijskog faktora VIII
(rDNK), turoktokoga alfa.
NovoEight 1000 IU prašak i otapalo za otopinu za injekciju
Jedna bočica s praškom nominalno sadrži 1000 IU humanog
koagulacijskog faktora VIII (rDNK),
turoktokoga alfa.
Nakon rekonstitucije, NovoEight sadrži približno 250 IU/ml humanog
koagulacijskog faktora VIII
(rDNK), turoktokoga alfa.
NovoEight 1500 IU prašak i otapalo za otopinu za injekciju
Jedna bočica s praškom nominalno sadrži 1500 IU humanog
koagulacijskog faktora VIII (rDNK),
turoktokoga alfa.
Nakon rekonstitucije, NovoEight sadrži približno 375 IU/ml humanog
koagulacijskog faktora VIII
(rDNK), turoktokoga alfa.
NovoEight 2000 IU prašak i otapalo za otopinu za injekciju
Jedna bočica s praškom nominalno sadrži 2000 IU humanog
koagulacijskog faktora VIII (rDNK),
turoktokoga alfa.
Nakon rekonstitucije, NovoEight sadrži približno 500 IU/ml humanog
koagulacijskog faktora VIII
(rDNK), turoktokoga alfa.
NovoEight 3000 IU prašak i otapalo za otopinu za injekciju
Jedna bočica s praškom nominalno sadrži 3000 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 19-05-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 19-05-2021
Public Assessment Report Public Assessment Report Bulgarian 29-01-2020
Patient Information leaflet Patient Information leaflet Spanish 19-05-2021
Public Assessment Report Public Assessment Report Spanish 29-01-2020
Patient Information leaflet Patient Information leaflet Czech 19-05-2021
Public Assessment Report Public Assessment Report Czech 29-01-2020
Patient Information leaflet Patient Information leaflet Danish 19-05-2021
Public Assessment Report Public Assessment Report Danish 29-01-2020
Patient Information leaflet Patient Information leaflet German 19-05-2021
Public Assessment Report Public Assessment Report German 29-01-2020
Patient Information leaflet Patient Information leaflet Estonian 19-05-2021
Public Assessment Report Public Assessment Report Estonian 29-01-2020
Patient Information leaflet Patient Information leaflet Greek 19-05-2021
Public Assessment Report Public Assessment Report Greek 29-01-2020
Patient Information leaflet Patient Information leaflet English 19-05-2021
Public Assessment Report Public Assessment Report English 29-01-2020
Patient Information leaflet Patient Information leaflet French 19-05-2021
Public Assessment Report Public Assessment Report French 29-01-2020
Patient Information leaflet Patient Information leaflet Italian 19-05-2021
Public Assessment Report Public Assessment Report Italian 29-01-2020
Patient Information leaflet Patient Information leaflet Latvian 19-05-2021
Public Assessment Report Public Assessment Report Latvian 29-01-2020
Patient Information leaflet Patient Information leaflet Lithuanian 19-05-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 19-05-2021
Public Assessment Report Public Assessment Report Lithuanian 29-01-2020
Patient Information leaflet Patient Information leaflet Hungarian 19-05-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 19-05-2021
Public Assessment Report Public Assessment Report Hungarian 29-01-2020
Patient Information leaflet Patient Information leaflet Maltese 19-05-2021
Public Assessment Report Public Assessment Report Maltese 29-01-2020
Patient Information leaflet Patient Information leaflet Dutch 19-05-2021
Public Assessment Report Public Assessment Report Dutch 29-01-2020
Patient Information leaflet Patient Information leaflet Polish 19-05-2021
Public Assessment Report Public Assessment Report Polish 29-01-2020
Patient Information leaflet Patient Information leaflet Portuguese 19-05-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 19-05-2021
Public Assessment Report Public Assessment Report Portuguese 29-01-2020
Patient Information leaflet Patient Information leaflet Romanian 19-05-2021
Public Assessment Report Public Assessment Report Romanian 29-01-2020
Patient Information leaflet Patient Information leaflet Slovak 19-05-2021
Public Assessment Report Public Assessment Report Slovak 29-01-2020
Patient Information leaflet Patient Information leaflet Slovenian 19-05-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 19-05-2021
Public Assessment Report Public Assessment Report Slovenian 29-01-2020
Patient Information leaflet Patient Information leaflet Finnish 19-05-2021
Public Assessment Report Public Assessment Report Finnish 07-08-2018
Patient Information leaflet Patient Information leaflet Swedish 19-05-2021
Public Assessment Report Public Assessment Report Swedish 29-01-2020
Patient Information leaflet Patient Information leaflet Norwegian 19-05-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 19-05-2021
Patient Information leaflet Patient Information leaflet Icelandic 19-05-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 19-05-2021

Search alerts related to this product

View documents history